The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients ≥ 50 years from the Czech acute leukaemia clinical register (alert)
Jindra, P, Muzik, J, Indrak, K, Zak, P, Sabty, F A, Kozak, T, Cetkovsky, P, Karas, V Koza M, Raida, L, Szotkowski, T
Published in Neoplasma (2013)
Published in Neoplasma (2013)
Get more information
Journal Article